{"disease":{"id":"solid-tumors-adult","name":"solid tumors adult"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04526106","title":"REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Elevar Therapeutics","has_results":false},{"nct_id":"NCT07417189","title":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":401,"lead_sponsor_name":"Abbisko Therapeutics Co, Ltd","has_results":false},{"nct_id":"NCT06404528","title":"Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Wuxi People's Hospital","has_results":false},{"nct_id":"NCT06916442","title":"Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT04621435","title":"Imaging of Solid Tumors Using FAP-2286","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":191,"lead_sponsor_name":"Thomas Hope","has_results":false},{"nct_id":"NCT07396584","title":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06800196","title":"A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":151,"lead_sponsor_name":"KinoTeck Therapeutics Co., Ltd","has_results":false},{"nct_id":"NCT07228247","title":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Hutchmed","has_results":false},{"nct_id":"NCT06378593","title":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"3H (Suzhou) Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT07385950","title":"Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT05861895","title":"HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"HighField Biopharmaceuticals Corporation","has_results":false},{"nct_id":"NCT05228015","title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT05432726","title":"Prediction of Chemotherapy Toxicity and Survival in Elderly Cancer Patients by CARG Score","phase":"","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05747339","title":"A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Wuxi People's Hospital","has_results":false},{"nct_id":"NCT04587479","title":"A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Jacobio Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04467853","title":"A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"Shanghai East Hospital","has_results":false},{"nct_id":"NCT06504368","title":"Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT05430373","title":"GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT05018273","title":"Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Nykode Therapeutics ASA","has_results":false},{"nct_id":"NCT00638898","title":"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06088472","title":"TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT07256756","title":"A Study of GC203 TIL in Advanced Solid Tumors (NF)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05354323","title":"NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"NEC OncoImmunity AS","has_results":false},{"nct_id":"NCT05698888","title":"Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Virtuoso BINco, Inc.","has_results":false},{"nct_id":"NCT05472220","title":"Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pamela Munster","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}